
TriLink Announces License Agreement with Lucigen Corporation

TriLink Announces License Agreement with Lucigen Corporation
Complete the form below and we will email you a PDF version of "TriLink Announces License Agreement with Lucigen Corporation"
TriLink BioTechnologies, Inc. and Lucigen Corporation have announced that the two companies have signed a licensing agreement for the use of TriLink’s CleanAmp™ dNTPs in Lucigen’s new Taq98™ Hot Start 2X MasterMix.
TriLink’s CleanAmp™ dNTPs are an innovative approach to Hot Start PCR. By simply replacing the standard dNTPs in a PCR assay with CleanAmp™ dNTPs, a Hot Start reaction can be achieved.
This universal approach to high stringency PCR offers a cost effective method to vastly reduce mis-priming, primer dimer formation and other common deleterious off-target effects in PCR.
Lucigen has offered its popular EconoTaq® DNA Polymerase and EconoTaq® PLUS 2X Master Mixes for several years, garnering a reputation for robustness and cost effectiveness.
As part of their mission to simplify genomic research, Lucigen has developed the new Taq98™ Hot Start 2X Master Mix for customers seeking to amplify difficult DNA templates, including targets with >70% GC content. The product is expected to be available for sale in mid-August.
“We believe Taq98™ represents a great combination of performance, ease-of-use, and value for the customer. The addition of the Hot Start feature has significantly increased the market for this product,” stated Jeff Williams, Lucigen President.
“We have found that CleanAmp™ dNTPs improve the performance of a number of thermostable DNA polymerases, allowing for simple conversion of any assay to a Hot Start version. We are pleased to find synergy between TriLink’s CleanAmp™ dNTPs and Lucigen’s amplification product line,” said Dr. Natasha Paul, TriLink Scientific Investigator.
“CleanAmp™ dNTPs are a unique molecular biology tool. As an alternative approach to Hot Start PCR, CleanAmp™ opens new doors for innovation. We are very pleased to be able to work with Lucigen to develop novel products with our combined technologies,” commented TriLink CEO, Dr. Richard Hogrefe.